2005
The Role of Substance Abuse in HIV Disease Progression: Reconciling Differences from Laboratory and Epidemiologic Investigations
Kapadia F, Vlahov D, Donahoe RM, Friedland G. The Role of Substance Abuse in HIV Disease Progression: Reconciling Differences from Laboratory and Epidemiologic Investigations. Clinical Infectious Diseases 2005, 41: 1027-1034. PMID: 16142670, DOI: 10.1086/433175.Peer-Reviewed Original ResearchConceptsHIV disease progressionDisease progressionEpidemiologic investigationsHIV/AIDS epidemicUse of licitEpidemiological studiesSubstance abuseStudy designDrug abuseAIDS epidemicCareful evaluationReview of findingsProgressionIllicit drugsLaboratory-based studiesMethodological strengthsFindingsAbuseMixed results
2003
Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy
Schreibman T, Friedland G. Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy. Clinical Infectious Diseases 2003, 38: 257-262. PMID: 14699459, DOI: 10.1086/380792.Peer-Reviewed Original ResearchConceptsTotal lymphocyte countCD4 cell countAntiretroviral therapyCell countLymphocyte countHuman immunodeficiency virus (HIV) diseaseOpportunistic infection prophylaxisPotential surrogate markerResource-limited settingsHIV diseaseInfection prophylaxisLaboratory markersOpportunistic infectionsSurrogate markerDisease progressionClinical utilityImmune functionTherapeutic interventionsTherapyKey laboratory measurementsMonitoring responseVirus diseaseLack of availabilityDiseaseCount